Dr James Millard Consultant in infectious diseases and general medicine

Background

Dr Millard studied medicine at Nottingham University and undertook training in Infectious Diseases and General Medicine in Edinburgh, Manchester and London. He undertook the Diploma in Tropical Medicine and Hygiene and an Masters in Tropical Medicine and International Health, both at the London School of Hygiene and Tropical Medicine.

 

Expertise

Tuberculosis, neurological and neurosurgical Infection, fever in returning travelers, bone and joint infection, outpatient intravenous antibiotic therapy (OPAT)

Research & publications

Dr Millard completed a PhD on the optimisation of treatment for tuberculosis through the University of Liverpool and Africa Health Research Institute in Durban, South Africa. He has an ongoing interest in tuberculosis, particularly focused on resistance and therapeutics. He has worked on a number of clinical trials and is the principal investigator for the RECOVERY trial of COVID therapeutics at Imperial.

Selected publications:

Millard J, Rimmer S, Nimmo C, O'Donnell M. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB. Emerg Infect Dis 2023

Millard J, Isralls S, Ryan H, Nevitt S, Davies G. WHO handbook on tuberculosis: module 4, annex 4: optimization of dosage of pyrazinamide in treatment of drug-susceptible tuberculosis: systematic review.

Nimmo C, Millard J, Faulkner V et al. Evolution of Mycobacterium tuberculosis drug resistance in the genomic era. Frontiers in Cellular and Infection Microbiology 2022

CRyPTIC Consortium. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis. European Respiratory Journal 2022

CRyPTIC Consortium. The 2021 WHO catalogue of M. tuberculosis complex mutations associated with drug resistance: A genotypic analysis. The Lancet Microbe 2022

Isralls S, Baisley K, Ngam E, Grant A, Millard J. QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study. Open Forum Infectious Diseases 2021

RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022

Nimmo C, Millard J, van Dorp L et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe 2020

Nimmo C, Millard J, Brien K et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. European Respiratory Journal 2020

Mthiyane T, Millard J, Adamson J et al. N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment. Antimicrobal Agents and Chemotherapy 2020